Oculis to Present at the Stifel 2024 Healthcare Conference
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees [Yahoo! Finance]